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Tackground: Transplant arteriosclerosis, the hallmark feature of chronic rejection, is
till the major limiting factor for the long-term success of heart transplantation.
latelets have been implicated to play a role in the pathogenesis of this disease.
herefore the aim of this study was to investigate whether platelet inhibition alone
as a positive effect on the development of transplant arteriosclerosis.
ethods: Fully major histocompatibility complex–mismatched C57BL/6 (H2b)
onor aortas were transplanted into CBA (H2k) recipients, and mice received
ifferent doses (1, 10, and 20 mg/kg) of clopidogrel or control saline as a daily
ntraperitoneal injection for 30 days. Blood was analyzed on days 2, 7, 14, and 30
y using a platelet aggregation test (adenosine diphosphate) for effectiveness of the
reatment. Grafts were analyzed by means of histology and morphometry on day 30
fter transplantation.
esults: When mice were treated daily with 1 mg/kg clopidogrel in the absence of
ny other immunosuppression, transplant arteriosclerosis was significantly reduced
ompared with that seen in saline-treated control animals (intimal proliferation of
6%  9% [1 mg/kg clopidogrel] vs 77%  5% [control], n  7, P  .03). Daily
pplication of 10 mg/kg and 20 mg/kg clopidogrel also significantly reduced the
evelopment of transplant arteriosclerosis compared with that seen in control
nimals (intimal proliferation of 61%  11% [10 mg/kg clopidogrel] vs 54% 
0% [20 mg/kg clopidogrel] vs 77%  5% [control], n  8, P  .003). There was,
owever, no additional beneficial effect when compared with mice treated with 1
g/kg clopidogrel (P  .06). Isografts did not show any signs of vascular lesions
n day 30 after transplantation.
onclusion: These results demonstrate that monotherapy with clopidogrel can
ffectively reduce the formation of transplant arteriosclerosis in a murine aortic
llograft model.
ransplant arteriosclerosis, the hallmark feature of chronic rejection, is still the
leading cause of late mortality and limits the long-term success of heart
transplantation.1 It is characterized by a diffuse and progressive thickening
f the arterial intima that affects minor, as well as major, coronary arteries of
ransplanted cardiac allografts.2,3 This results in sudden or chronic progressive
schemic damage to the transplanted heart, with subsequent organ failure. As the
ransplanted heart is denervated, the first clinical manifestations of transplant
rteriosclerosis might be progressive heart failure, ventricular arrhythmia, or sudden
ardiac death. Transplant arteriosclerosis is diffuse and frequently involves long
egments of the affected arteries. In contrast to ordinary arteriosclerosis, which
sually affects one part of the artery more severely than other parts and produces
rominent lesions, transplant arteriosclerosis is characterized by concentric intimal
hickening.2,3
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1
TXNumerous pathogenetic mechanisms have been suggested
o be involved in the development of transplant arterioscle-
osis, including immune-mediated vascular injury, inflam-
ation of the vascular endothelium, ischemia-reperfusion
njury, cytomegalovirus infection, and metabolic risk fac-
ors.2,3 The role of platelets during the development of
rdinary arteriosclerosis is meanwhile established,4,5 and
nteractions of platelets with the endothelium induce signif-
cant changes in the adhesive and chemotactic properties of
ndothelial cells that trigger monocyte adhesion and trans-
igration. This results in early inflammation during the
rocess of arteriosclerosis within the vessel wall,6,7 and
herefore recent interest has focused on the involvement of
latelets in the pathogenesis of transplant arteriosclerosis.
hile comparing the results of intracoronary ultrasono-
raphic examinations and platelet analyses from patients
ndergoing heart transplantation, Fateh-Moghadam and
olleagues8 showed that platelet activation by increased
xpression of ligand-induced binding site 1 was strongly
ssociated with the development and progression of trans-
lant arteriosclerosis. In a similar study Hognestad and
ssociates9 could demonstrate an enhanced expression of
-selectin, CD63, and soluble CD154 by platelets from
atients undergoing heart transplantation severely affected
y transplant arteriosclerosis.
Clopidogrel, a member of the thienopyridines, has be-
ome an important therapeutic agent for patients with cor-
nary heart disease10,11 and has been shown to decrease the
ncidence of coronary artery stent thrombosis and to reduce
yocardial infarction, stroke, and vascular death within
hese patients.11 It inhibits platelet activation by blocking an
denosine diphosphate (ADP) receptor on platelets, recently
esignated P2Y12.12,13 Clopidogrel is inactive in vitro and
equires hepatic metabolism for production of its active
etabolite, which has also been identified recently.14 It
eems unlikely that the clinical benefit of this drug can be
dequately explained by its ability to decrease ADP-induced
latelet aggregation alone, suggesting that other not yet
efined mechanisms, such as a platelet-mediated inflamma-
ory reaction, might play a role.13
This study tested the hypothesis as to whether treatment
ith clopidogrel (Plavix, Sanofi-Synthelabo, Berlin, Ger-
any) alone results in a significant reduction of transplant
rteriosclerosis. Mouse abdominal aortic allografts were
sed as the experimental model because they have been
Abbreviations and Acronyms
ADP  adenosine diphosphate
CD40L CD40 ligand
PDGF  platelet-derived growth factorhown to represent vascular lesions similar to those ob- a
162 The Journal of Thoracic and Cardiovascular Surgery ● Maerved in human coronary arteries that are affected by
ransplant arteriosclerosis and therefore allow a precise
nalysis of the composition of the vascular lesions.15
aterials and Methods
nimals
57BL/6 (H2b) and CBA.J (H2k) mice were originally purchased
rom Charles River (Sulzbach, Germany). C57BL/6 (H2b) mice
ere used as donors, and CBA.J (H2k) mice were used as recip-
ents of the aortic allografts. All mice used in this study were aged
etween 6 and 12 weeks at the time of experimental use and were
red and maintained at the animal facility of the Department of
xperimental Surgery at the University of Erlangen-Nuernberg
nder specific pathogen-free conditions and treated in accordance
ith institutional and state guidelines.
reatment Protocol
lopidogrel (Plavix) was obtained from the local hospital phar-
acy, and 75-mg tablets were dissolved in 0.9% saline under
terile conditions. This solution was then diluted appropriately in
he following concentrations: group 1, 1 mg/kg clopidogrel equiv-
lent of a human daily dose; group 2, 10 mg/kg clopidogrel; and
roup 3, 20 mg/kg clopidogrel. Daily treatment with clopidogrel
as started immediately after transplantation for 30 days. Because
issolved clopidogrel is unstable,14 the clopidogrel solution was
reshly prepared every day and injected intraperitoneally immedi-
tely after preparation. The overall injection volume was 0.5 mL
or each treatment group.
latelet Aggregation
or ex vivo platelet aggregation, blood was collected in 3.2% citrate.
pproximately 0.5 mL of blood could be obtained from each
ouse, and samples were immediately processed after blood draw-
ng. Platelet aggregation was evaluated by means of optical aggre-
ometry in citrated blood samples at 37°C by using a 2-channel
hronolog aggregometer Elvi Logos, Milan, Italy. Because mice
ave slightly more platelets compared with human subjects, for
echnical reasons, the amount of citrate within the test tubes was
ncreased to 500 L of citrate (500 L citrate/500 L blood) for
x vivo platelet aggregation. Therefore in our setting even un-
reated control animals showed a relative reduction of platelet
ggregation to about 50%. However, this did not affect absolute
ifferences seen in platelet aggregation between the experimental
roups. Platelet-rich and platelet-poor plasma was prepared from
itrated whole blood by means of centrifugation (100g for 10
inutes). The final platelet count was adjusted to an average of
.5  105 platelets/mL with autologous plasma. Twenty microli-
ers of ADP Sigma, St Louis, Mo; final concentration, 2  104
ol/L, respectively was added to induce platelet activation, and
ggregation was recorded for at least 10 minutes. Maximal aggre-
ation was mostly seen around 5 minutes and was used as a
easurement of aggregation.
bdominal Aortic Transplantation
he procedure was performed with a modified technique initially
escribed by Koulack and coworkers.16 In brief, the donor thoracic
orta was isolated, resected, and transferred to the recipient animal.
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TXhe recipient aorta was clamped and then transected with sharp
icrovascular scissors. A proximal end-to-end anastomosis was
erformed. The aortic graft was then repositioned, and the anas-
omosis was continued with single interrupted sutures.
nalysis of the Aortic Graft
ortic grafts were removed after achievement of anesthesia on
ays 14 and 30 after transplantation. Grafts were perfused with
aline and were flash frozen in OCT medium (Tissue-Tek, Sakura,
etherlands) in liquid nitrogen for morphometric analysis of 5-m
ryostat sections. A minimum of 10 transverse sections was ana-
yzed from each graft.
orphometry
ive sections from each graft harvested at days 14 and 30 were
tained with Elastin–van Gieson and analyzed by 2 independent
xaminers (S.A. and S.M.E.) blinded to the experimental condi-
ions at an original magnification of 200 using a conventional
ight microscope. A digitized image of each section was captured,
nd the areas within the lumen and the internal and external elastic
amina were circumscribed manually and measured as previously
escribed.17 All image analyses were carried out on a color display
onitor with ANAlysis Image Analysis software (Olympus, Ham-
urg, Germany).
tatistical Analysis
esults are given as the mean per group  standard deviation,
hich was derived from the mean per graft. The data were ana-
yzed by using a 2-tailed unpaired Student t test.
esults
latelet Aggregation Was Effectively Inhibited After
lopidogrel Administration
x vivo blood samples were harvested on days 2, 7, 14, 21,
nd 30 to evaluate the effect of clopidogrel on platelet
unction and to ensure sufficient platelet aggregation inhi-
ition within the CBA/J recipient mice. Aggregation was
etermined by means of light transmittance aggregometry in
esponse to ADP (2  104 mol/L, Figure 1). Blood drawn
rom recipient mice treated with 1, 10, and 20 mg/kg clo-
idogrel showed significantly reduced platelet aggregation
n day 2 (26% 7% [1 mg/kg clopidogrel, n 5, P  .05]
s 12%  4% [10 mg/kg clopidogrel, n  5, P  .03] vs
%  3% [20 mg/kg clopidogrel, n 5, P  .01] vs 45% 
% [control]) and day 7 (16%  4% [1 mg/kg clopidogrel,
 5, P  .03] vs 9%  2% [10 mg/kg clopidogrel, n 
, P  .01] vs 4%  1% [20 mg/kg clopidogrel, n  5,
 .001] vs 48%  4% [control]) after transplantation
Figure 1). Application of 10 mg/kg and 20 mg/kg clopi-
ogrel also significantly reduced platelet aggregation com-
ared with 1 mg/kg clopidogrel on day 2 (12%  4% [10
g/kg clopidogrel, n  5, P  .05] vs 9%  3% [20 mg/kg
lopidogrel, n  5, P  .03] vs 26%  7% [1 mg/kg
lopidogrel]) and day 7 (9%  2% [10 mg/kg clopidogrel,
 5, P  .05] vs 4%  1% [20 mg/kg clopidogrel, n  w
The Journal of Thoracic, P  .03] vs 16%  4% [1 mg/kg clopidogrel]; Figure 1).
rom day 14 onward, platelet aggregation in all groups was
ignificantly inhibited compared with that seen in untreated
ontrol animals, and there were no differences between 1,
0, and 20 mg/kg clopidogrel (Figure 1). Blood from un-
reated control animals showed unimpaired platelet function
hroughout all time points (Figure 1).
lopidogrel Significantly Reduced the Development
f Transplant Arteriosclerosis
total of 58 transplantations were performed for this study,
ith an overall complication rate of 6.8%, the most frequent
omplication being thrombosis of the aortic graft (n  3)
nd one late recipient death caused by other courses. Aortic
llografts (C57BL/6 [H-2b]) from recipients (CBA/J [H-2k])
ere analyzed 30 days after transplantation, the time point
t which distinctive changes of transplant arteriosclerosis
re most evident.18 When recipient mice were treated daily
ith 1 mg/kg clopidogrel in the absence of any other im-
unosuppression, transplant arteriosclerosis was signifi-
antly reduced compared with that seen in untreated control
nimals (intimal proliferation of 66%  9% [1 mg/kg
lopidogrel] vs 77%  5% [control], n  8, P  .03;
igures 2, B and C, and 3). Daily application of 10 mg/kg
nd 20 mg/kg clopidogrel also significantly reduced the
evelopment of transplant arteriosclerosis compared with
hat seen in untreated control animals (intimal proliferation
f 61%  11% [10 mg/kg clopidogrel, n  8, P  .003] vs
4%  10% [20 mg/kg clopidogrel, n  8, P  .001] vs
7%  5% [control]; Figures 2, D and E, and 3). However,
here was no additional beneficial effect when compared
0
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igure 1. Effect of clopidogrel on adenosine diphosphate (ADP)–
nduced platelet aggregation in mice after transplantation. Plate-
et aggregation was studied after stimulation with ADP (20
mol/L) by means of light transmittance aggregometry. *P < .05
ersus untreated control animals, **P < .03 versus untreated
ontrol animals, ***P< .01 versus untreated control animals (n
animals per group).ith mice treated with 1 mg/kg clopidogrel (P  .06,
and Cardiovascular Surgery ● Volume 131, Number 5 1163
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TXigure 3). Syngeneic control grafts (C57BL/6 [H2b] into
57BL/6 [H2b] recipients) did not show any signs of trans-
lant arteriosclerosis at 30 days after transplantation, indi-
ating that nonimmunologic mechanisms alone were not
ufficient to initiate the development of transplant arterio-
clerosis in this model (Figure 2, A). None of the recipient
ice showed any kind of hemorrhage or major postopera-
ive bleeding.
iscussion
he development of transplant arteriosclerosis in cardiac
llografts is a multifactorial process, with macrophages, T
ells, proinflammatory cytokines, adhesion molecules, growth
actors, and alloantibodies implicated in both the initiation
nd progression of this chronic inflammatory process.3,19 It
igure 2. Histopathologic evaluation of the morphology of un-
reated fully allogeneic C57BL/6 aortic grafts implanted into CBA
ecipients showed high levels of intimal proliferation (B),
hereas C57BL/6 aortic grafts of recipients treated with 1 mg/kg
lopidogrel (C), 10 mg/kg clopidogrel (D), and 20 mg/kg clopi-
ogrel (E) showed significantly reduced intimal proliferation 30
ays after transplantation. Syngeneic control animals did not
how any vascular lesions (A). The tissue was snap-frozen, and
ections were stained with Miller’s Elastin–van Gieson stain.
Original magnification 200.)s well established nowadays that platelets play an important a
164 The Journal of Thoracic and Cardiovascular Surgery ● Maole in thrombus formation and atherogenesis, but several
tudies suggest that these cells might also play an important
ole in inflammation.6,20
This study demonstrates that (1) treatment with different
oses of clopidogrel significantly inhibited platelet aggre-
ation in a murine aortic allograft model, (2) that mono-
herapy with clopidogrel significantly reduced the develop-
ent of transplant arteriosclerosis in the absence of any
dditional immunosuppression, and (3) that there was no
ignificant beneficial effect when the daily clopidogrel dose
as increased. The level of reduction of intimal prolifera-
ion by clopidogrel was as effective as anti-CD8 T-cell
epletion.17 These findings imply that circulating platelets
n recipients with aortic transplants might contribute to the
evelopment of transplant arteriosclerosis.
Three different treatment groups (1, 10, and 20 mg/kg)
ere examined to find the most effective dose of clopi-
ogrel for the prevention of transplant arteriosclerosis. Ad-
inistration of 1 mg/kg clopidogrel, the equivalent of a human
aily dose, already showed a strong platelet aggregation
nhibitory effect and resulted in a significant reduction of
ransplant arteriosclerosis. Kinetic analysis revealed that
igher doses of clopidogrel caused a more rapid inhibition
f platelet aggregation but failed to prove an additional
herapeutic effect. These results imply that reduction of the
evelopment of transplant arteriosclerosis by clopidogrel
ight not be entirely due to its ability to decrease ADP-
nduced platelet aggregation, suggesting that additional im-
unomodulatory effects, such as a platelet-mediated in-
ammatory reaction, might play a role.13
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igure 3. For the morphometric analysis of the degree of intimal
hickening, Miller’s Elastin–van-Gieson–stained sections were
sed. Areas within the lumen and the internal and external
lastic lamina were circumscribed manually and measured. From
hese measurements, a quotient for the thickness of the intima
Qint) was calculated. Qint indicates the relative thickness (in
ercentage) of the intima. Five measurements from different areas
f each aortic graft were obtained for this analysis. (n  8
nimals per group, P values as indicated in the diagram).
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TXActivated platelets are able to release a number of in-
ammatory compounds from their granules, such as P-
electin21 and platelet-derived growth factor (PDGF),22 that
an activate monocytes, granulocytes, and endothelial cells,
ll contributing to a systemic inflammatory response in
arious pathologic conditions, such as transplant arterio-
clerosis.3,19 In addition, platelets can induce enhanced sur-
ace expression of adhesion receptors, such as intercellular
dhesion molecule 123 and E-selectin24 on endothelial cells
hat mediate adhesion and transmigration of leukocytes, an
ssential step during the development of transplant arterio-
clerosis.25 Furthermore, activated platelets contain high
evels of intracellular soluble CD40 ligand (CD40L).6 Most
f these molecules have been shown to be involved in the
athogenesis of transplant arteriosclerosis.
Experimental data from carotid artery allografts have
emonstrated that intracellular adhesion molecule 1 plays a
ritical role through modulation of leukocyte adhesion and
nfiltration into the vessel wall.26 During chronic rejection
n a murine heterotopic cardiac allograft model, the intensity
f arterial intimal thickening was significantly correlated
ith the intensity of P-selectin expression on endothelial cells,
nd therefore a crucial role for P-selectin in the pathogen-
sis of transplant arteriosclerosis by augmenting immune-
ediated injury was concluded.27 In addition, Lemstrom
nd associates28 showed that suppression of PDGF expres-
ion inhibited the development of transplant arteriosclerosis
hrough regulation of cell migration and proliferation. Fi-
ally, the importance of CD40L-CD40 interaction during
he development of transplant arteriosclerosis has been
ighlighted in numerous experimental studies.29,30
In a prospective clinical study Fateh-Moghadam and
olleagues8 found that transplant arteriosclerosis in patients
eceiving heart transplants was associated with enhanced
brinogen receptor activation (ligand-induced binding site
) and P-selectin surface expression of the circulating plate-
ets. These authors concluded that increased activation of
irculating platelets in these patients might contribute to the
evelopment and progression of transplant arteriosclerosis.
imilar results were obtained by Hognestad and coworkers,9
emonstrating enhanced expression of P-Selectin and solu-
le CD40L by analyzing platelet activation in long-term
urvivors of heart transplantation. They could also show that
eart transplant recipients were characterized by a persistent
mmune activation even several years after transplantation,
uggesting that enhanced platelet activation might have
ontributed to this inappropriate immune activation after
eart transplantation.
Clopidogrel inhibits platelet activation by blocking the
2Y12 ADP receptor on platelets.12 Analysis of the relation-
hip between P-selectin expression and PDGF secretion in
uman platelets revealed that treatment with clopidogrel re-
ulted in downregulation of P-selectin expression and re-
The Journal of Thoracicuced PDGF secretion.31 When patients with anti-thy1 glo-
erulonephritis were treated with clopidogrel, they showed
ignificantly limited extracellular matrix deposition, as well
s transforming growth factor 1 expression,32 both patho-
ogic mechanisms involved in the formation of transplant
rteriosclerosis.30,33 Recently, it was also shown that ad-
inistration of clopidogrel reduced P-selectin and CD40L
xpression in an experimental rabbit ischemic coronary
rtery model.34 Experiments to further clarify and under-
tand the underlying pathologic mechanisms of the benefi-
ial effect of clopidogrel on the development of transplant
rteriosclerosis are currently ongoing in our laboratory.
owever, we already think at this stage that effective anti-
latelet strategies might be a reasonable addition to the
linical therapy to improve the long-term outcome of heart
ransplantation.
In conclusion, we have shown that monotherapy with
lopidogrel can effectively reduce the formation of trans-
lant arteriosclerosis in a murine aortic allograft model.
urthermore, clopidogrel is a readily available and widely
sed drug with an established clinical safety profile. These
ndings therefore have important clinical implications be-
ause patients who are predisposed to or have transplant
rteriosclerosis after cardiac transplantation might substan-
ially benefit from treatment with this drug.
We thank Professor Michael Stuerzl for permission to use his
acilities and Mr Johannes Roesch for expert technical assistance.
e also thank Dr Dirk Labahn and the staff of the animal facility
f the University of Erlangen-Nuernberg for their expert care of
nimals used for this study.
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